Salivary and urinary excretion and plasma-saliva concentration ratios of isoniazid in the presence of Co-administered ciprofloxacin. 2002

Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria.

Salivary and urinary excretion and plasma-saliva concentration ratios of isoniazid (INH) in the absence and presence of ciprofloxacin (CP) were investigated in healthy female volunteers. Results obtained indicated an absorption form of interaction between INH and CP. This led to delay in gastric emptying and onset of absorption of INH in the upper part of the gastrointestinal tract, resulting in a corresponding delay in the onset of salivary and urinary excretion of the drugs. There was a 1-hour reduction in the time to attain peak saliva concentration of INH (tmax), an insignificant difference in peak saliva concentration (Cmax), and a significant (P = 0.05) increase in AUC(0-24h) of INH in the presence of CP. Cumulative amount of INH excreted in the urine increased approximately 38% in the presence of CP. The calculated plasma-saliva concentration ratios of INH were reduced in the presence of CP and were slightly lower than the experimental values. This indicates increased amount of the drug secreted into saliva in the presence of CP and possible buccal partitioning of the drug. Overall, results of the current study indicate that CP delayed the onset but not the extent of INH absorption. Therefore, concurrent administration of the two drugs was considered relatively safe, and the absorption interaction that may have occurred may not be of reasonable clinical consequence.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012463 Saliva The clear, viscous fluid secreted by the SALIVARY GLANDS and mucous glands of the mouth. It contains MUCINS, water, organic salts, and ptylin. Salivas
D019540 Area Under Curve A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992) AUC,Area Under Curves,Curve, Area Under,Curves, Area Under,Under Curve, Area,Under Curves, Area

Related Publications

Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
January 2004, American journal of therapeutics,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
January 1972, Therapie,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
January 1985, Indian journal of physiology and pharmacology,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
October 1971, Masui. The Japanese journal of anesthesiology,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
January 1969, Annales medicinae experimentalis et biologiae Fenniae,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
March 1985, Chemical & pharmaceutical bulletin,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
March 1989, Journal of pharmacobio-dynamics,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
June 1956, Journal of the American Pharmaceutical Association. American Pharmaceutical Association,
Sabinus I Ofoefule, and Chioma E Obodo, and Orish E Orisakwe, and Johnson O Afonne, and Ndidiamaka A Ilondu, and Patrick U Agbasi, and Chikere A Anusiem, and Steve O Maduka, and Cajetan E Ilo
January 1956, Blood,
Copied contents to your clipboard!